{
    "clinical_study": {
        "@rank": "124527", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: AP26113 (90 mg)", 
                "arm_group_type": "Experimental", 
                "description": "AP26113 will be administered to eligible patients at a dose of 90 mg once daily, continuously."
            }, 
            {
                "arm_group_label": "Arm B: AP26113 (90 mg /180 mg)", 
                "arm_group_type": "Experimental", 
                "description": "AP26113 will be administered to eligible patients at a dose of 90 mg once daily, then 180 mg once daily, continuously."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of two different dosing\n      regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)-positive locally\n      advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on\n      therapy with crizotinib."
        }, 
        "brief_title": "A Multicenter Study (ALTA) of AP26113", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small Cell Lung Cancer", 
            "Lung Cancer", 
            "Advanced Malignancies", 
            "Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, phase 2, open-label, multicenter, international study to evaluate the\n      efficacy and safety of two different dosing regimens of AP26113 in patients with\n      ALK-positive, locally advanced or metastatic NSCLC who have previously been treated with\n      crizotinib.\n\n      The primary objective of the study is to determine the efficacy of AP26113, as evidenced by\n      confirmed objective response rate (ORR).  Two dosing regimens will be tested.  The secondary\n      objectives of the study (for each dosing regimen) include overall survival (OS);\n      progression-free survival (PFS); safety and tolerability.  It is estimated that accrual will\n      be complete within 18 months; the total estimated duration of the study is 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Have histologically or cytologically confirmed locally advanced or metastatic NSCLC\n             that is ALK+.\n\n          2. Had progressive disease while on crizotinib, as assessed by the investigator or\n             treating physician.\n\n          3. Received crizotinib as the last therapy.\n\n          4. Have at least 1 measurable lesion per RECIST.\n\n          5. Previously received 0 to 3 lines of cytotoxic chemotherapy for advanced disease.\n\n          6. \u226518 years old.\n\n          7. Life expectancy \u22653 months.\n\n          8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n\n          9. Must provide a signed and dated informed consent indicating that the patient has been\n             informed of all pertinent aspects of the study, including the potential risks, and is\n             willingly participating.\n\n        Key Exclusion Criteria:\n\n          1. Received any prior ALK-targeted TKI other than crizotinib.\n\n          2. Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days,\n             except SRS or stereotactic body radiosurgery.\n\n          3. Received monoclonal antibodies or had major surgery within 30 days of the first dose\n             of AP26113.\n\n          4. Have been diagnosed with another primary malignancy within the past 3 years.\n\n          5. Have meningeal involvement or spinal cord compression.\n\n          6. Have a history or the presence of pulmonary interstitial disease or drug-related\n             pneumonitis.\n\n          7. Have CNS metastases that are symptomatic, neurologically unstable, or   require an\n             increasing dose of corticosteroids\n\n          8. Have significant, uncontrolled, or active cardiovascular disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "218", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094573", 
            "org_study_id": "AP26113-13-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: AP26113 (90 mg)", 
                "description": "90 mg, taken orally once daily,continuously", 
                "intervention_name": "AP26113 (90 mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: AP26113 (90 mg /180 mg)", 
                "description": "90 mg tablet, taken orally once daily, then a 180 mg tablet taken orally once daily, continuously", 
                "intervention_name": "AP26113 (90 mg /180 mg)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Non-small cell lung cancer", 
            "Non-small cell lung carcinoma", 
            "Epithelial lung cancer", 
            "Squamous cell carcinoma", 
            "Large cell carcinoma", 
            "Adenocarcinoma", 
            "Anaplastic lymphoma kinase (ALK)", 
            "Advanced Malignancies", 
            "Carcinoma", 
            "Anaplastic Lymphoma Kinase (ALK)", 
            "Advanced Cancers", 
            "AP26113"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Karen Reckamp", 
                    "phone": "626-471-9200"
                }, 
                "contact_backup": {
                    "last_name": "Sharon Denison", 
                    "phone": "626-256-4673", 
                    "phone_ext": "63298"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope, Site #009"
                }, 
                "investigator": {
                    "last_name": "Karen Reckamp, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Han Koh", 
                    "phone": "562-461-6941"
                }, 
                "contact_backup": {
                    "last_name": "James Chow", 
                    "phone": "619-528-6832"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92108"
                    }, 
                    "name": "Kaiser Permanente, Site #208"
                }, 
                "investigator": {
                    "last_name": "Han Koh, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Ross Camidge", 
                    "phone": "720-848-0449"
                }, 
                "contact_backup": {
                    "last_name": "Melinda Friesleben", 
                    "phone": "720-848-0579"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Cancer Center, Site #015"
                }, 
                "investigator": {
                    "last_name": "David Ross Camidge, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", 
        "overall_contact": {
            "email": "Christopher.Turner@ariad.com", 
            "last_name": "Christopher Turner, M.D.", 
            "phone": "617-494-0400"
        }, 
        "overall_contact_backup": {
            "email": "Frank.Haluska@ariad.com", 
            "last_name": "Frank Haluska, M.D., PhD", 
            "phone": "617-494-0400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Canada: Health Canada", 
                "Denmark: Danish Health and Medicines Authority", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hong Kong: Department of Health", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Singapore: Health Sciences Authority", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Spain: Spanish Agency of Medicines", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Defined as the composite of complete response (CR) and partial response (PR). To assess objective response rate in the total patient population.", 
            "measure": "Objective response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Confirmed \u22654 weeks after initial response. Up to 3 years."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined as the interval between enrollment and death due to any cause, censored at the last contact date.  To assess OS in the total patient population.", 
                "measure": "Overall survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Defined as the duration of time from start of study drug administration to time of objective disease progression or death due to any cause, whichever may come first.  To assess PFS in the total patient population.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Measured by incidence of adverse events (AEs).  To evaluate the safety and tolerability of AP26113 in the total patient population.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Ariad Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ariad Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}